Tuesday, July 21, 2020

Pfizer Inc and BioNTech SE Get $1.95 Billion Covid-19 Vaccine Order From U.S. Government


Pfizer Inc : NYSE (PPE)

CMP- 36.69


Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines.
>> Pfizer Inc. and BioNTech SE stated Wednesday they have signed a $1.95 billion settlement with the U.S. Department of Health and Human Services and the Defense Department to invulnerable lots of thousands and thousands of doses of a Covid-19 vaccine which Americans would acquire for free.

Price of Pfizer Inc on NYSE on daily charts


 Recent earning of Pfizer in the quarter ending March 2020


> For the three months ended 29 March 2020, Pfizer Inc. revenues decreased 8% to $12.03B. Net income decreased 12% to $3.4B.

> Revenues reflect Upjohn segment decrease of 34% to $2.02B, Other/Unallocated and wirldwide segment decrease from $858M to $0K

> United States segment decrease of 8% to $5.65B, Developed Rest of World segment decrease of 5% to $1.46B.

Pfizer and BioNTech SE agrrement with U.S. Department of Health and Human Services and the Defense Department

Pfizer Inc. and BioNTech SE stated Wednesday they have signed a $1.95 billion settlement with the U.S. Department of Health and Human Services and the Defense Department to invulnerable lots of thousands and thousands of doses of a Covid-19 vaccine which Americans would acquire for free.
๐Ÿ‘‰   Under the agreement, the U.S. authorities would get hold of one hundred million doses of BNT162, the Covid-19 vaccine candidate mutually developed by using Pfizer and BioNTech, and can gather up to five hundred million extra doses. Pfizer would make the vaccine.

๐Ÿ‘‰The BNT162 software is primarily based on BioNTech's proprietary mRNA science and supported by way of Pfizer's international vaccine improvement and manufacturing capabilities. The BNT162 vaccine candidates are present process medical research and don't seem to be presently permitted for distribution somewhere in the world.

➽The Pfizer-BioNTech vaccine improvement application is evaluating at least 4 experimental vaccines. If the research are successful, Pfizer and BioNTech anticipate to are trying to find emergency use authorization or some structure of regulatory approval as early as October.

๐Ÿ‘‰The organizations presently count on to manufacture globally up to one hundred million doses by means of the quit of 2020 and doubtlessly greater than 1.3 billion doses through the stop of 2021, challenge to closing dose decision from their medical trial.

No comments:

Post a Comment